E3330 is a REF-1 selective inhibitor that interferes with disulfide bond formations between cysteine residues within the active site of APEX1’s redox domain [51] and is currently being used in different clinical trials as cancer treatment (NCT0337508, NCT03375086). Here, APEX1 is linked to cancer.